40 results about "CD43" patented technology

The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Le^a structure, a Le^a-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.

A method for efficient generation of neutrophils, eosinophils, macrophages, osteoclasts, dendritic cells an Langerhans cells from human embryonic stem cells is disclosed.

The invention discloses a real-time fluorescence quantitative PCR(Polymerase Chain Reaction) detection kit and related primers for thalassemia genes. The kit comprises more than one pair of the following primers: SEQ ID NO.1 and SEQ ID NO.2 aiming at TATA kits nt-28 (A->G) (-28M), -29 (A->G) (-29M) and CAP-40-43 (AACC) (CAPM) genotypes; SEQ ID NO.3 and SEQ ID NO.4 aiming at CD14-15 (+G) (14-15M), CD17 (A->T) (17M) and the initiation codon mutant ATG->AGG(IntM) genotypes; SEQ ID NO.5 and SEQ ID NO.6 aiming at CD26 (G->A)(betaEM) CDs27-28+C(27-28M), IVS1-1(G->T)(IVS1-1M), IVS1-5(G->C)(IVS1-5M) genotypes; SEQ ID NO.7 and SEQ ID NO.8 aiming at CDs41-42-TCTT (41-42M), CD43G->T(43M), 41-42M/41-42M genotypes; SEQ ID NO.9 and SEQ ID NO.10 aiming at CD71-72(+A) (71-72M) genotypes; SEQ ID NO.11 and SEQ ID NO.12 aiming at IVS2-654C->T(654M) and 654M/654M genotypes; and SEQ ID NO.13 and SEQ ID NO.14 aiming at constant spring (CS), Quong Sze (QS) and Westmead (WS) genotypes. The kit has the advantages of good detection specificity and high detection sensitivity.

The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.

There is described herein a method of enriching a population of stem cells for hematopoietic progenitors. The method comprises inducing hematopoietic differentiation in a population of human embryonic stem cells or human induced pluripotent stem cells; sorting the population based on expression of CD43 and at least one of CD34, CD31 and CD144; and selecting a fraction that is at least one of CD34+CD43−, CD31+CD43− and CD144+CD43−. Also provided are populations of hematopoietic progenitors obtained by the methods described herein.

The invention discloses a method for increasing the efficiency of inducing pluripotent stem cells to be differentiated into hematopoietic stem cells in vitro. The method comprises the steps of carrying out in-vitro co-culture on OP9 and iPSCs, and meanwhile, adding trophic factors such as SCF, BMP4, IL-3, IL-6 and TPO into a differential medium. By using the method, the double positive rate of CD34+ CD43+ is increased to 15.3%, the differentiation efficiency is remarkably increased, and therefore, iPSCs can be induced to be differentiated into hematopoietic stem cells through adding a positive regulating factor, and the differentiation efficiency can be conveniently and rapidly increased only through a cell factor adding method.

The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.

The invention provides an agent comprising: (i) a T cell antigen, and (ii) a binding partner for any of CD22, CD23, CD30, CD74, CD70, CD43, CD44, CD47, CD54, CD58, CD62L, CD95, HLA-DR, CD59, CD55, wherein, following binding of the agent to a cell that expresses any of CD22, CD23, CD30, CD74, CD70, CD43, CD44, CD47, CD54, CD58, CD62L, CD95, HLA-DR, CD59, CD55, the agent is internalised and the T cell antigen is presented on the surface of the cell in a form that can be recognised by a T cell.

The invention discloses a rapid detection kit aiming at thalassemia mutant genes common in Chinese crowds. The rapid detection kit comprises primers designed aiming at <SEA>, <THAI>, alpha<2.4>, alpha<21.9>, HPFH SEA and DBT, primers designed aiming at alpha<4.2> and alpha<3.7> and primers designed aiming at alpha<CS>alpha, alpha<QS>alpha, alpha<Westmead>alpha, beta< 90>, beta< 29>, beta< 28>, beta<Cap+40 43>, beta<Int M>, beta<Int CD>, beta<CD14 15>, beta<CD17>, beta<CD26>, beta<27/28>, beta<IVS I 1>, beta<IVS I 5>, beta<CD37>, beta<CD41 42>, beta<CD43>, beta<CD71-72>, beta<CD95> and beta<IVS II 654>. The kit can quickly and accurately detect the thalassemia mutant genes common in Chinese crowds.

The invention discloses a kit for rapid detection of common mutant genes of thalassemia. The kit includes primers designed specific to --<SEA>, --<THAI>, -alpha<2.4>, -alpha<21.9>, HPFH-SEA, DBT, -alpha<4.2>, -alpha<3.7>, alpha<CS>alpha, alpha<QS>alpha, alpha<Westmead>alpha, Hb Q-Thailand, beta<-90>, beta<-29>, beta<-28>, beta<Cap+40-43>, beta<Int M>, beta<Int CD>, beta<CD14-15>, beta<CD17>, beta<CD26>, beta<27/28>, beta<IVS-I-1>, beta<IVS-I-5>, beta<CD37>, beta<CD41-42>, beta<CD43>, beta<CD71-72>, beta<CD95>, and beta<IVS-II-654> and gender detection primers, and the primers are subpackaged in 2 tubes. The kit provided by the invention can rapidly and accurately detect the common mutant genes of thalassemia.

The invention relates to a non-isotope method for testing point mutation, which uses DNA molecule inner hybrid probe and the connected primer. The invention has been completely used to detest known eleven ª‰ thalassemia point mutation and two ª‡ thalassemia point mutation, that is: -28(A-G), -29(A-G), CD17(A-T), CD26(G-A, HbE), CD30(A-G), CDs41/42(-TTCT), CD43(G-T), CDs71/72(+A), CD95(+A), IVS-I-1(G-T)IVS-II-654(C-T), CD125(CTG-CCG, Hb Quong Sze) and terminating codon(TAA-CAA, Hb Constant Spring).

Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a.

The invention discloses application of a histone deacetylase inhibitor in preparation of products for promoting differentiation of pluripotent stem cells into hematopoietic stem and progenitor cells.According to the application, differentiation of pluripotent stem cells of every 104 personscan be promoted to produce 15.7% of CD31+CD43+hematopoietic stem and progenitor cells, which are nearly 4 times more than those ofa control group, the generation efficiency of the hematopoietic stem and progenitor cells is also significantly higher than thatof thehematopoietic stem and progenitor cellsof the general range,generatedafter promotion by other small molecules in the prior art, the treatment time is short, the maneuverability and the repeatability are higher, and the hematopoietic stem and progenitor cells can be efficiently and rapidly generated in vitro. According to the application of the histone deacetylase inhibitor in preparation of the products for promoting differentiation of thepluripotent stem cells into the hematopoietic stem and progenitor cells, by adding the officinal HDAC inhibitor at the early stage of differentiation, the serum-free and matrix-free mode of highly-controllably and efficiently generating the hematopoietic stem and progenitor cells at a low costlays a foundation for large-scale production of functional blood cells for clinical treatment in the future.

Disclosed are methods of preparing CD34+CD43+ hematopoietic progenitor cells (HPC) in vitro according to embodiments of the invention. Also disclosed are methods of differentiating CD34+CD43+ hematopoietic progenitor cells to hematopoietic lineage cells according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e.g., cancer, according to embodiments of the invention.

The invention discloses a kit for quickly detecting beta Mediterranean anemia mutant alleles common in Chinese population. The kit comprises primers designed for deletion-type beta Mediterranean anemia genes HPFH-SEA and G gamma+(A gamma delta gamma)0, primers designed for non-deletion-type Mediterranean anemia alleles beta-90, beta-29, beta-28, beta Cap+40-43, beta Int M, beta Int CD, beta CD14-15, beta CD17, beta CD26, beta 27/28, beta IVS-I-1, beta IVS-I-5, beta CD37, beta CD41-42, beta CD43, beta CD71-72, beta CD95 and beta IVS-II-654 and AMXY primer for detecting gender. The kit can quickly and accurately detect the beta Mediterranean anemia mutant alleles common in the Chinese population.